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1 |  BACKGROUND
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare dis-
order of hematopoietic stem cells causing intravascular he-
molysis. We report about a patient with PNH treated with 
eculizumab during pregnancy. Experience on safety and effi-
cacy of eculizumab in pregnancy is scarce. Our case supports 
its benefit on fetal and maternal outcome so far.
Paroxysmal nocturnal hemoglobinuria is very rare, with 
a prevalence of 1- 2 cases per million people with a slight 
female predominance.1 PNH can affect women of child-
bearing age and may be diagnosed during pregnancy for 
the first time.2 It is a non- neoplastic human disease caused 
by a somatic mutation of the x- linked phosphatidylinositol 
glycan- complementation class A (PIG- A) gene in hemato-
poietic stem cells, which renders red blood cells susceptible 
to complement- mediated hemolysis.3 It causes a chronic pro-
gressive disease characterized by hemolytic anemia, venous 
thromboembolism, and bone marrow failure.2 During preg-
nancy, terminal complement formation is increased, causing 
a higher morbidity than in nonpregnant women with PNH, 
with the requirement for more frequent transfusions.4
Paroxysmal nocturnal hemoglobinuria is diagnosed by 
detection of GPI (Glycosylphosphatidylinositol) negative 
cells in peripheral blood using flow cytometry with fluores-
cent aerolysin (FLAER).5 In addition, bone marrow analysis 
(including cytogenetics) is needed to detect other underlying 
bone marrow disorders (eg, myelodysplastic syndrome or 
aplastic anemia). Clinical diagnosis can be difficult as PNH 
has a wide range of symptoms and signs, which can be con-
founded with various complications seen in pregnancy, for 
example, preeclampsia, HELLP syndrome, or pregnancy- 
associated thrombocytopenia. PNH should always be sus-
pected in pregnant women with unexplained severe anemia, 
thrombocytopenia, and signs of hemolysis. It is important 
to distinguish a HELLP syndrome from a PNH crisis, which 
both can show similar symptoms such as nausea, abdominal 
pain, and pathological laboratory findings of hemolysis (el-
evated lactate dehydrogenase (LDH) and indirect bilirubin, 
low haptoglobin, and low platelets).
Clinical trials in nonpregnant patients with PNH have 
shown that eculizumab prevents disease complications and 
improves quality of life and overall survival.6,7 Eculizumab is 
a humanized monoclonal antibody that blocks the activation 
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of terminal complement at C5 and prevents the formation of 
C5a and the terminal complement complex C5b- 9. The drug 
has been approved by the FDA in the United States in March 
2007 and by the European Medicines Agency in June 2007.
Prior to the approval of eculizumab by the FDA and the 
European Commission, there were no approved therapeu-
tic options for patients with PNH. Treatment was generally 
supportive in nature.8,9 Without treatment, median survival 
after diagnosis was limited to 10- 32 years, primarily due to 
thromboembolic events. Regarding the application of eculi-
zumab during pregnancy, it has shown a low rate of maternal 
complications up to now. However, there is little expertise 
in managing pregnant patients with PNH with eculizumab, 
especially as prospective trials are unlikely to be initiated, 
as PNH is a very rare disease.10,11 The drug is still listed in 
pregnancy as a category C drug, but potential benefits may 
outweigh potential risks. It is reported in the literature that ec-
ulizumab infusion protocols had to be adjusted in the courses 
of pregnancies by higher doses or shortening of application 
intervals. This could possibly be explained by dilutional ef-
fects, as plasma volume and complement levels increase 
during pregnancy.
As there are still few studies about the outcomes of preg-
nancies in patients with PNH, who were treated with ecu-
lizumab, we present such a case and review the existing 
literature to share clinical information and compare our treat-
ment protocol.
2 |  CASE PRESENTATION
At the age of 25 years, the patient presented herself in her first 
pregnancy at 37 + 3 weeks of gestation at a small primary 
care hospital with fever 3 days after rupture of the amniotic 
membranes. As an incidental finding the patient showed a 
thrombocytopenia (40 G/L) of unknown origin. Therefore, 
she was transferred to a secondary care hospital, where a ce-
sarean delivery in general anesthesia was performed the same 
day, due to a pathological cardiotocography, suspected amni-
otic infection and thrombocytopenia. Because of postpartum 
anemia the patient required two red blood cell transfusions. 
The newborn suffered from asphyxia, followed by infection, 
and generalized convulsions caused by a cerebral infarction in 
the right frontotemporal lobe. However, recovery of the neo-
nate was good with normal further development. The mother 
suffered from a persistent bicytopenia and fatigue after birth. 
She was followed up in an outpatient setting at a secondary 
care center, where further diagnostics were initiated. Initial 
bone marrow biopsy in our patient revealed an increased 
and megaloblastic erythropoiesis with moderate dyserythro-
poietic and dysmegacaryopoietic changes. The karyotype of 
bone marrow cells was normal (46, XX). She was referred 
to the hematological department of our tertiary care center. 
A second bone marrow biopsy confirmed the morphological 
and cytogenetic findings of the first puncture. Furthermore, 
FLAER of peripheral blood detected a significant PNH popu-
lation with 94% of granulocytes. Besides, the patient showed 
gross hematuria. All together, the results were interpreted as 
classical PNH. At the end, the diagnosis of PNH was stated at 
an age of 27, not earlier than 18 months after the appearance 
of her first signs and symptoms during her first pregnancy.
An initial immunosuppression with thymoglobulin for 
6 days and cyclosporine for about 2.5 months was ineffective 
in reducing hemolytic activity, but in contrast caused serum 
sickness. Therefore, treatment with the relatively new drug 
eculizumab was initiated 5 months after PNH was diagnosed, 
and ever since continued biweekly. The PNH clone was mea-
sured yearly and decreased from 94% to 80% in the following 
2 years. Eculizumab treatment significantly reduced hemo-
lytic activity. Conditions deemed optimal for conception as 
the patient was planning another pregnancy. For this, prenatal 
counseling was done by both a specialist in high- risk preg-
nancies and a specialized hematologist.
As prophylaxis against venous thromboembolism the pa-
tient received an oral anticoagulation with a vitamin K an-
tagonist (Phenprocoumon, 3 mg/d), which was switched to 
a therapy with low molecular weight heparin (Dalteparin) 
6 months later as the patient presented with a positive preg-
nancy test. Prior to conception, the patient had already re-
ceived eculizumab continuously for 32 months. Eculizumab 
was continued throughout the entire pregnancy. The patient 
had biweekly surveillance at our hematological department 
before and after pregnancy with application of 900 mg eculi-
zumab and laboratory check- ups to detect hemolysis. During 
pregnancy monitoring was intensified to intervals of 10 days 
as hemolysis occurred in the second trimester, requiring 2 
red blood cell transfusions and the application of eculizumab 
in shorter intervals (10- 11 days) (Table 1). The PNH clone 
has not been monitored during pregnancy. As a result of the 
intenser therapy, anemia improved and the level of LDH de-
creased. Pregnancy monitoring was primarily performed by 
an obstetrician in private practice. These controls were done 
in standard intervals of 3- 4 weeks. Ultrasound check- ups in-
cluding nuchal translucency, detailed sonomorphology, and 
Doppler sonography of the great vessels were always incon-
spicuous. The patient developed gestational diabetes requiring 
insulin and a mild hypertension in the third trimester, but with 
no need for antihypertensive therapy, as the blood pressure 
was only intermittent and marginally high. The patient was 
referred to our obstetrical department at 36 + 0 gestational 
weeks because of a rising blood pressure of 150/95 mm Hg. 
There were no clinical signs of preeclampsia, but altered 
laboratory results with high LDH, low platelets, and low he-
moglobin. As PNH could have been the cause of these alter-
ations but also could have masked a beginning preeclampsia/
HELLP syndrome, further clinical monitoring has been done. 
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During clinical observation blood pressure returned to nor-
mal and laboratory parameters remained stable, so that a pre-
eclampsia/HELLP syndrome could be excluded. There were 
also no signs of fetal anemia. At 36 + 0 gestational weeks 
anti- C and anti- M antibodies were detected, which had been 
negative in the first trimester prior to blood transfusions. In 
the follow- up control at 36 + 6 weeks levels of anti- C were 
always low (titer 1:16, in tubule 1:4) and anti- M antibodies 
no more detectable (with cutoffs of 1:16). Anti- C antibodies 
remained positive ever since. Neither thromboembolic events 
occurred during gestation nor in the postpartum period. A 
healthy neonate of low birth weight (2730 g) was born by 
scheduled cesarean at 37 + 0 gestational weeks because of 
persistent transverse presentation of the fetus. The cesarean 
was performed in general anesthesia because of thrombocyto-
penia (106 G/L) combined with significant local hematomas 
in the patient after daily injection of dalteparin. Cesarean sec-
tion was uneventful with an estimated blood loss of 400 mL 
and patient’s recovery was excellent. Hemoglobin level be-
fore surgery was 106 g/L and 88 g/L 24 hours after surgery. 
The course of pregnancy with its therapy and changes in lab-
oratory findings is shown in Figure 1.
Direct antiglobulin testing (DAT) turned out posi-
tive (++) in the neonate, but no hemolytic reaction re-
quiring therapy occurred in the newborn. As the positive 
DAT has been interpreted as an A0 incompatibility by the 
T A B L E  1  Detailed course of laboratory changes and treatment during pregnancy
Gestation (wk + d)/
postpartum Hemoglobin (g/L) Platelets (G/L) LDH (U/L)
Eculizumab (+ 
interval in days)
Red cell 
transfusion
2 + 4 103 144 585 900 mg/iv (+14)
4 + 4 99 160 484 900 mg/iv (+14)
6 + 4 94 150 850 900 mg/iv (+14)
8 + 4 94 152 1904 900 mg/iv (+14)
9 + 2 88 155 900 mg/iv (+12)
10 + 4 89 156 1851 900 mg/iv (+12)
12 + 4 87 158 1847 900 mg/iv (+14)
14 + 1 83 140 1841 900 mg/iv (+10)
15 + 4 83 164 1068 900 mg/iv (+10)
17 + 1 82 121 1272 900 mg/iv (+10)
18 + 4 80 116 1416 900 mg/iv (+10) 1 EC
20 + 1 86 112 1599 900 mg/iv (+10)
21 + 4 85 135 1326 900 mg/iv (+10) 1 EC
23 + 1 92 124 1346 900 mg/iv (+10)
24 + 4 98 122 1362 900 mg/iv (+10)
26 + 1 99 137 1348 900 mg/iv (+10)
27 + 4 99 116 1595 900 mg/iv (+10)
29 + 1 100 106 1994 900 mg/iv (+10)
30 + 4 97 107 2110 900 mg/iv (+10)
32 + 1 107 95 1288 900 mg/iv (+10)
33 + 4 109 100 1170 900 mg/iv (+10)
35 + 1 106 98 1073 900 mg/iv (+10)
35 + 4 108 108 765 900 mg/iv (+10)
36 + 0 107 103 900 mg/iv (+10)
37 + 0 (date of delivery) 105 118
Postpartum day 5 86 147 900 mg/iv (+14)
Postpartum day + 11 85 136 1909 900 mg/iv (+14)
Postpartum day + 25 102 138 2203 900 mg/iv (+14)
Postpartum day + 39 98 135 1700 900 mg/iv (+14)
Postpartum day + 53 102 115 1965 900 mg/iv (+14)
Postpartum day + 67 110 132 1336 900 mg/iv (+14)
LDH, lactate dehydrogenase.
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neonatologists, no follow- up was required. The patient de-
clined breastfeeding, so lactation was inhibited directly 
postpartum by administration of cabergoline. At the time 
of dismissal, the patient decided to use condoms for further 
birth control.
Three weeks after birth anticoagulation was changed back 
from low molecular weight heparin (dalteparin) to a vitamin 
K antagonist (phenprocoumon 3 mg/d). During hospitaliza-
tion, the patient had been co- managed with our colleges of 
the hematological department and was followed up there 
10 days after dismissal with blood testing and eculizumab ad-
ministration. Eculizumab has been continued biweekly ever 
since postpartum.
3 |  DISCUSSION
Ten years ago, PNH was associated with a high mortality 
and morbidity. Especially in pregnancy mortality rate has 
shown to be high (8%- 20%), mostly because of fatal throm-
botic events. As a consequence, pregnancy was generally dis-
couraged, as maternal mortality has been reported between 
8%- 20.8%, primarily due to thromboembolic events, which 
mainly occurred in the postpartum period. Fetal morbidity 
and mortality were also high (4%- 9%), which was mainly re-
lated to a high rate of preterm birth. Birth weight <3 kg has 
been described in 53% of the cases.12,13
When eculizumab was established in 2007, patients suf-
fering from PNH suddenly could regain normal life expec-
tation and quality, so that reproduction became an option 
for some female patients again. As eculizumab trials have 
always excluded pregnant patients, the effect of the drug for 
mother and child was unknown in the beginning. Single case 
reports on pregnant women suffering from PNH, whom ec-
ulizumab had been administered, have suggested a favorable 
outcome.14-18 In our case, we observed comparable positive 
findings. Results were encouraging but clinical data were not 
yet sufficient to draw conclusions.
Finally, in 2015, a retrospective study was published eval-
uating the use of eculizumab in pregnant women and their 
born children by data of a designed questionnaire, that was 
sent to members of the International PNH group and phy-
sicians participating in the International PNH registry.11 
Seventy- five pregnancies in 61 women between 2008 and 
2014 were analyzed. No maternal deaths occurred, fetal mor-
tality rate was 4% and premature birth was reported in 29%. 
The dose of eculizumab or the frequency of its application 
had to be increased in 54% after the first trimester because 
of breakthrough hemolysis. The demand for blood transfu-
sion increased from 0.14 monthly units before pregnancy to 
0.92 during gestation and platelet transfusions were required 
in 16 cases. Ten clinically significant bleeding episodes were 
documented in the third trimester, postpartum hemorrhage 
in 8 cases. No thrombotic events occurred during pregnancy 
compared to 2 out of 75 cases (3%) in the postpartum period. 
In both cases, eculizumab had been stopped after birth and in 
one case the thrombotic event occurred under LMWH ther-
apy. Sixty- nine children have been evaluated by development 
assessment. One child showed transient asymptomatic neu-
tropenia and another preterm born a slightly delayed develop-
ment of speech. The presence of eculizumab has been detected 
in several cord- blood samples, but there was no evidence of 
complement blockade in the newborn.15 So far, the drug was 
not detected in breastmilk samples.11,14 Overall, there are no 
reported serious adverse effects in neonates, whose mothers 
were treated with eculizumab during the entire pregnancy, 
but still more long- term follow- up of the infants is needed.11 
Comparing our data with this study above and other case re-
ports, we find a comparable course. We can report, that in 
our case no thrombotic events took place, neither during ges-
tation nor in the postpartum period. However, breakthrough 
hemolysis occurred in our patient and eculizumab had to be 
administered in shorter intervals. Blood transfusion require-
ments were increased in pregnancy, as the patient needed two 
units in her second trimester compared to a transfusion- free 
interval since the implementation of eculizumab therapy 
F I G U R E  1  Course of changes 
in hemoglobin, platelets and lactate 
dehydrogenase (LDH) concentration during 
pregnancy
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before pregnancy. The patient developed symptomatic throm-
bocytopenia, which did not require platelet transfusion, but 
therefore cesarean had to be performed in general anesthesia. 
Another similarity we found was the absence of adverse fetal 
outcome despite eculizumab exposure. Fortunately, the child 
in our case could be delivered at term as no further compli-
cations occurred. Eculizumab had a protective effect without 
causing any adverse reaction in our case.
Anyhow, we need more specific guidelines for the man-
agement of such high- risk pregnancies. Comparing reviews 
and case reports, several authors mention the following help-
ful considerations for the management of pregnancies in pa-
tients with PNH. Because the disorder is associated with high 
maternal and fetal morbidity, all fertile female patients should 
be counseled about possible risks during pregnancy. The 
pregnancy controls should ideally be performed by an obste-
trician specialized in high- risk pregnancies in collaboration 
with a hematologist.19 Folic acid should be supplemented, 
as constant hemolysis causes an increased demand. PNH is 
associated with iron deficiency, therefore iron replacement is 
also recommended.19 As transfusion requirements are usually 
more frequent during pregnancy with PNH, it is important to 
avoid complement- rich blood products in order to avoid he-
molytic crisis and to use washed red blood cells and platelets 
instead.
Anticoagulation still remains an essential component of 
the therapy for pregnant patients with PNH, as the risk for 
thromboembolic events with fatal outcome is relatively high. 
Most authors recommend the use of low molecular weight 
heparin, starting in the first trimester and with maintenance 
throughout the postpartum period of 4- 6 weeks, as we did in 
our case.
Furthermore, it has to be questioned if anticoagulation is 
necessary in a patient on eculizumab therapy, as it effectively 
inhibits hemolysis and therefore might prevent thromboem-
bolic events sufficiently. As breakthrough hemolysis has still 
been described in patients under eculizumab with the require-
ment of adjustments in the dosage or intervals, it might not be 
safe to abstain from anticoagulation. To avoid hemorrhagic 
events in the peripartal period an adjustment of anticoagu-
lant therapy has to be considered. Monitoring of thrombotic 
markers is recommended during the treatment.
So far, experiences with eculizumab have been favorable 
as thromboembolic events and complications could be re-
duced. As the drug has a long half- life (10- 12 days) dosing is 
challenging in gestation due to the physiological changes in 
blood and plasma volume and coagulation factors. Therefore, 
parameters of hemolysis as LDH need to be surveilled closely. 
Nevertheless, there is no clear statement if the drug can be 
recommended in all pregnant patients with PNH. In a patient 
with a very big PNH clone size or with signs of hemolysis the 
drug mostly outweighs the risks for complications associated 
with PNH. However, it is unknown, if a pregnant patient with 
a rather small clone size should be treated with eculizumab 
during pregnancy, considering the possible risk for adverse 
effects on the neonate. In most patients, eculizumab has been 
initialized at a granulocyte clone size of 20% and higher.17 
Birth should be recommended in a hospital with a special-
ized hematological support and an obstetrical unit with ex-
perience in high- risk pregnancies. Vaginal birth is preferred 
whenever possible, as the risk of thromboembolic events is 
lower after vaginal birth compared to a cesarean. Concerning 
analgesia, it needs to be considered that regional anesthesia 
might not be feasible in a state of severe thrombocytopenia 
or because of the application timing of LMWH therapy. 
Inducing labor may allow a more controlled situation for 
delivery. Breastfeeding is interpreted as safe as eculizumab 
is not excreted into breastmilk.11 However, much more case 
reports will be necessary for a better understanding of the 
effects of the drug in patients and their offspring to finally 
be able to establish general guidelines of managing pregnant 
patients with PNH in the best manner.
4 |  CONCLUSION
Summing up the use of eculizumab during pregnancy in our 
case and the reported cases so far, it has shown favorable 
results, which are encouraging for female patients with PNH 
who wish to become pregnant. Nevertheless, more evidence 
is required to prove the safety of eculizumab for mother and 
child and to establish a more effective management during 
pregnancy.
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